No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
397 |
4. Check minimum number of eventsNone |
397 |
5. Include endpointsNone |
397 |
6. Filter based on genotype QC (FinnGen only) |
389 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- D35
- Name in latin
- Neoplasma benignum glandulae parathyreoideae
Similar endpoints
↥List of similar endpoints to
Benign neoplasm: Parathyroid gland
based on the number of shared cases.
Similar with more cases:
- Benign neoplasm of other and unspecified endocrine glands
- Benign neoplasms
- Neoplasms
- Any operation in hilmo
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 2464 | 1832 | 617 |
| Only index persons | 2183 | 1635 | 548 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.04 | 0.05 | 0.02 |
| Only index persons | 0.05 | 0.06 | 0.02 |
| Median age at first event (years) | |||
| Whole population | 63.70 | 64.32 | 61.99 |
| Only index persons | 62.91 | 63.38 | 61.51 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 389 | 275 | 114 |
| Unadjusted period prevalence (%) | 0.08 | 0.10 | 0.05 |
| Median age at first event (years) | 61.48 | 60.31 | 64.32 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 397
- Matched controls
- 3970
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
BBA30
NOMESCO Finland
Excision of lesion of parathyroid gland
286.1
307.7
213
16
D35.1
ICD-10 Finland
Benign neoplasm: Parathyroid gland
+∞
307.7
364
*
E21.09
ICD-10 Finland
Other primary hyperparathyroidism
84.8
295.0
162
32
E21.0
ICD-10 Finland
Primary hyperparathyroidism
64.7
251.6
145
35
E21.3
ICD-10 Finland
Hyperparathyroidism, unspecified
81.8
174.3
94
15
E83.50
ICD-10 Finland
Hypercalcemia
41.5
87.7
54
15
BBA20
NOMESCO Finland
Exploration of parathyroid gland
93.0
45.0
49
6
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
4.4
45.0
258
1181
A11CC03
ATC
alfacalcidol; systemic
13.4
39.9
39
32
BBA40
NOMESCO Finland
Subtotal parathyroidectomy
75.9
36.7
41
6
BAA40
NOMESCO Finland
Unilateral lobectomy of thyroid gland
9.9
34.8
42
47
E21.2
ICD-10 Finland
Other hyperparathyroidism
59.8
32.9
38
7
2271A
ICD-9 Finland
Benign neoplasm of other endocrine glands and related structures, Parathyroid gland
+∞
30.6
29
*
D35.0
ICD-10 Finland
Benign neoplasm: Adrenal gland
11.1
29.3
32
31
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
4.8
26.9
68
164
H05BX01
ATC
cinacalcet; oral
41.8
25.3
31
8
Z46.8
ICD-10 Finland
Fitting and adjustment of other specified devices
8.1
25.0
35
47
EP1AE
NOMESCO Finland
Neck ultrasound examination
5.1
24.9
57
126
2522
FHL
Removal of parathyroidism or multiple parathyroidism (including removal of adenoma or total removal)
138.7
24.9
26
*
ZXD10
NOMESCO Finland
Scheduled procedure
2.8
22.9
214
1161
321
Kela drug reimbursment
Paricalcitol and cinacalcet
34.6
22.7
29
9
BB1BQ
NOMESCO Finland
Extensive scintigraphy of parathyroid gland, 2 isotopes, SPECT and low-dose CT
85.0
21.9
24
*
E21
ICD-10 Finland
Hyperparathyroidism and other disorders of parathyroid gland
121.8
21.8
23
*
WX408
NOMESCO Finland
General anesthesy, balanced
2.7
19.4
150
726
E04.9
ICD-10 Finland
Nontoxic goitre, unspecified
8.2
17.6
24
31
N20.0
ICD-10 Finland
Calculus of kidney
11.5
14.2
26
24
N18.8
ICD-10 Finland
Other chronic renal failure
7.0
14.2
22
33
ZXE00
NOMESCO Finland
One hour or less
2.2
13.9
188
1134
D35.2
ICD-10 Finland
Benign neoplasm: Pituitary gland
17.0
13.6
21
13
N18.9
ICD-10 Finland
Chronic kidney disease, unspecified
3.9
13.4
41
113
KH1AD
NOMESCO Finland
CT of urinary organs
5.4
13.4
27
53
AAE10
NOMESCO Finland
Transsphenoidal total or partial excision of intracranial lesion
41.6
13.2
16
*
123
Kela drug reimbursment
Chronic disorders of vitamin D metabolism
9.5
12.4
25
28
J38.0
ICD-10 Finland
Paralysis of vocal cords and larynx
10.1
12.4
24
25
WX402
NOMESCO Finland
General anaesthesia
2.4
12.0
101
494
N20.9
ICD-10 Finland
Urinary calculus, unspecified
9.0
11.7
24
28
N20.1
ICD-10 Finland
Calculus of ureter
5.1
11.6
25
52
CA1TM
NOMESCO Finland
Calculation of intraocular lens power
10.1
11.4
22
23
KAT00
NOMESCO Finland
Extracorporeal shock wave lithotripsy of pelvis of kidney
20.8
11.2
16
8
Z03.80
ICD-10 Finland
Observation for other suspected diseases and conditions
4.9
11.1
25
54
K99
ICPC
Cardiovascular disease other
5.8
10.8
20
36
ZXE10
NOMESCO Finland
More than one and less than three hours
2.0
10.5
174
1104
2520A
ICD-9 Finland
Disorders of parathyroid gland, Hyperparathyroidism
112.9
10.5
11
*
AA4CG
NOMESCO Finland
Extensive MRI examination of sella turcica with high intensity magnet
19.4
10.3
15
8
WX199
NOMESCO Finland
Other local analgesia
4.6
9.7
23
52
TDW99
NOMESCO Finland
Other minor procedure in surgery of ear, nose and larynx
4.3
9.6
25
61
UDQ12
NOMESCO Finland
Flexible laryngoscopy
3.3
9.3
36
116
106
Kela drug reimbursment
Hypoparathyroidism
37.6
9.1
11
*
138
Kela drug reimbursment
Severe anaemia associated with chronic renal failure
7.7
9.0
20
27
E04.2
ICD-10 Finland
Nontoxic multinodular goitre
3.8
8.7
27
75
Z94.0
ICD-10 Finland
Kidney transplant status
28.2
8.5
11
*
KH1AA
NOMESCO Finland
Urinary tract X-ray examination without contrast
8.8
8.4
17
20
E11.2
ICD-10 Finland
Type 2 diabetes mellitus, with renal complications
4.3
8.4
22
54
N10
ICD-10 Finland
Acute tubulo-interstitial nephritis
2.4
8.3
65
304
XCW99
NOMESCO Finland
Other investigative procedure of eye
2.5
8.3
57
252
E66.8
ICD-10 Finland
Other obesity
3.6
8.2
28
83
V03AE02
ATC
sevelamer; oral
34.1
8.1
10
*
A12AA04
ATC
calcium carbonate; oral
8.0
8.0
17
22
XCH00
NOMESCO Finland
Eye pressure measurement
3.2
7.6
31
103
E23.00
ICD-10 Finland
Panhypopituitarism
25.6
7.6
10
*
E89.2
ICD-10 Finland
Postprocedural hypoparathyroidism
25.6
7.6
10
*
J01MA02
ATC
ciprofloxacin; systemic
1.8
7.5
165
1118
190
Kela drug reimbursment
Lanthanum carbonate, sevelamer and sucroferric oxyhydroxide
13.7
7.4
12
9
N39.0
ICD-10 Finland
Urinary tract infection, site not specified
2.1
7.3
77
407
BA1AE
NOMESCO Finland
Thyroiid ultrasound examination
7.5
7.3
16
22
H02AB09
ATC
hydrocortisone; systemic
4.6
7.2
17
38
M04AA01
ATC
allopurinol; systemic
2.2
7.2
62
302
E66.01
ICD-10 Finland
Obesity due to excess calories
2.7
7.2
41
165
A11CC02
ATC
dihydrotachysterol; oral
30.6
7.2
9
*
196
Kela drug reimbursment
Paricalcitol and cinacalcet
30.6
7.2
9
*
101
Kela drug reimbursment
Anterior pituitary hypofunction
20.5
7.2
10
5
E21.5
ICD-10 Finland
Disorder of parathyroid gland, unspecified
20.5
7.2
10
5
KA1AE
NOMESCO Finland
Kidney ultrasound examination
6.2
7.2
18
30
127
Kela drug reimbursment
Transplant complication
10.3
7.1
13
13
M05BA04
ATC
alendronic acid; oral
2.3
6.9
53
246
Z49.0
ICD-10 Finland
Preparatory care for dialysis
11.2
6.8
12
11
KBV12
NOMESCO Finland
Transluminal endoscopic removal of stent from ureter
9.6
6.8
13
14
ZY020
NOMESCO Finland
Telephone, letter or other consultation without direct patient contact
2.7
6.8
38
151
I10
ICD-10 Finland
Essential (primary) hypertension
1.8
6.8
269
2140
KAS10
NOMESCO Finland
Allogenic transplantation of kidney from cadaver donor
23.0
6.7
9
*
R4110, ,
SPAT
2.4
6.6
47
210
WX404
NOMESCO Finland
Intravenous generell anesthesy
1.9
6.6
96
567
N30.0
ICD-10 Finland
Acute cystitis
2.0
6.6
76
415
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
1.8
6.5
153
1046
D34
ICD-10 Finland
Benign neoplasm of thyroid gland
14.6
6.4
10
7
D64.9
ICD-10 Finland
Anaemia, unspecified
2.3
6.4
49
227
Z49.1
ICD-10 Finland
Extracorporeal dialysis
8.4
6.4
13
16
D44.1
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Adrenal gland
8.4
6.4
13
16
KBE12
NOMESCO Finland
Transluminal endoscopic extraction of calculus of ureter
11.3
6.3
11
10
BBA50
NOMESCO Finland
Total parathyroidectomy
+∞
6.3
6
*
D44.2
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Parathyroid gland
+∞
6.3
6
*
C75.0
ICD-10 Finland
Malignant neoplasm: Parathyroid gland
+∞
6.3
6
*
KA2AE
NOMESCO Finland
Ultrasound examination transplanted kidney
27.1
6.2
8
*
TCG40
NOMESCO Finland
Measurement of higher-grade errors of refraction
27.1
6.2
8
*
R2130
NOMESCO Finland
Counselling and guidance which enhance independent living
2.5
6.2
41
177
E89.01
ICD-10 Finland
Postsurgical hypothyroidism
5.9
6.2
16
28
H03AA01
ATC
levothyroxine sodium; systemic
1.8
6.1
113
719
PBL10
NOMESCO Finland
Construction of arteriovenous fistula from radial artery
8.8
6.1
12
14
ZXE05
NOMESCO Finland
Procedure duration 40 to 49 minutes
3.0
6.0
26
90
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
128
73
25.40
165.02
2.1
1.6
6.95
3.79
mmol/24h
8.62
109
61
201
272
13.94
156.06
6.7
3.2
119.56
74.81
ng/l
3.92
182
241
175
412
6.81
77.25
9.8
4.8
0.93
1.05
mmol/l
4.15
163
386
326
1751
5.82
46.33
18.8
6.3
1.27
1.22
mmol/l
17.91
300
1511
290
1448
4.72
44.68
4.2
2.2
79.19
79.89
nmol/l
0.17
275
1269
66
129
5.94
33.38
2.7
1.7
—
—
—
0
0
69
141
5.71
33.27
2.8
1.9
—
—
—
0
0
230
1219
3.11
27.08
4.1
3.4
2.45
2.36
mmol/l
8.52
212
1065
156
683
3.12
25.46
3.3
3.1
2.54
2.46
mmol/l
6.23
146
602
162
828
2.62
18.60
2.9
2.2
—
—
—
0
0
243
1507
2.58
18.49
8.5
4.3
36.12
35.44
g/l
1.50
230
1400
241
1600
2.29
14.19
3.1
2.5
—
—
—
0
0
133
718
2.28
12.63
5.2
2.4
3.95
5.99
e6/l
1.04
126
645
58
214
3.00
12.02
4.5
3.5
5.12
5.12
kpa
0.00
58
209
110
558
2.34
12.01
2.2
1.9
—
—
—
0
0
123
655
2.27
11.97
4.1
4.0
110.61
287.76
ng/l
0.99
88
526
233
1610
2.08
11.35
11.5
5.4
1.27
1.22
mmol/l
12.77
225
1456
337
2699
2.64
11.34
10.9
7.5
85.16
78.24
u/l
0.59
323
2514
267
1955
2.12
10.95
8.5
9.2
4.09
4.10
e9/l
0.03
235
1713
228
1601
2.00
10.19
5.6
5.9
27.02
27.60
%
0.32
219
1494
51
198
2.81
9.60
4.1
3.6
1.20
1.94
mmol/l
0.83
42
152
144
888
1.98
9.13
5.0
2.7
3655.48
7462.26
umol/l
0.51
135
763
161
1040
1.92
8.84
5.5
3.0
89.67
103.31
e6/l
0.05
140
784
62
277
2.47
8.80
3.2
3.1
233.61
214.35
ng/l
0.11
57
253
221
1589
1.88
8.65
5.5
5.6
57.97
57.57
%
0.18
212
1484
115
670
2.01
8.47
2.0
1.7
980.82
1224.45
nmol/l
2.35
95
497
164
1078
1.89
8.45
4.9
3.1
7.37
6.99
mmol/l
0.45
145
889
263
2028
1.88
7.96
7.1
4.4
6.46
6.71
mmol/l
1.73
255
1903
63
303
2.28
7.55
13.0
3.2
1.88
2.38
mmol/l
0.61
56
252
201
1446
1.79
7.46
2.3
2.0
101.88
95.84
pmol/l
0.72
114
712
178
1239
1.79
7.36
5.5
3.0
—
—
—
0
0
121
750
1.88
7.28
1.7
1.7
1.00
1.16
mg/l
0.38
95
586
311
2574
1.96
7.08
6.8
4.3
14.50
12.70
mm/h
1.18
298
2349
10
6
17.05
6.77
1.4
1.0
—
—
—
0
0
222
1683
1.72
6.53
17.6
14.1
1.32
1.25
inr
0.66
114
481
129
840
1.79
6.51
3.6
2.1
2.49
3.28
mg/l
4.88
116
722
365
3242
2.56
6.42
23.1
13.6
71.89
77.78
ml/min/173m2
4.30
323
2644
316
2666
1.91
6.29
5.2
4.0
14.28
14.91
pmol/l
3.91
296
2402
359
3172
2.38
6.28
6.2
4.9
1.84
1.95
mu/l
0.96
338
2871
158
1113
1.70
5.93
4.3
2.3
63.34
61.27
u/l
0.10
149
1024
32
127
2.65
5.78
2.7
2.0
2.54
3.04
g/l
1.35
25
117
34
142
2.52
5.55
2.5
1.9
3.47
3.54
g/l
0.10
27
132
34
142
2.52
5.55
2.6
1.9
—
—
—
0
0
34
142
2.52
5.55
2.6
1.9
7.78
7.44
g/l
0.44
27
132
77
462
1.83
4.97
4.9
2.4
19.83
22.80
%
1.69
72
397
152
1102
1.61
4.89
5.8
3.9
11.56
8.13
mg/mmol
0.59
110
658
55
300
1.97
4.73
2.0
3.0
67.88
66.46
g/l
0.64
45
275
66
387
1.85
4.57
3.4
4.8
221.18
263.38
u/l
1.16
61
363
33
152
2.28
4.38
2.5
2.3
38.61
40.06
u/l
0.14
28
134
17
57
3.07
4.17
1.4
1.2
—
—
—
0
0
11
21
5.36
4.17
1.9
1.5
99.09
77.71
umol/l
0.82
11
21
146
1081
1.55
4.16
2.3
2.1
234.96
181.78
u/l
0.23
133
1011
184
1439
1.52
4.05
4.8
2.7
153.36
130.40
ug/l
0.70
175
1310
23
93
2.56
4.04
1.2
1.3
—
—
—
0
0
256
2148
1.54
4.04
3.6
3.0
55.83
49.43
u/l
0.42
241
1975
90
597
1.66
4.03
1.3
1.3
7.87
11.35
u/ml
0.22
38
225
29
131
2.31
4.03
2.2
2.0
10.88
10.36
g/l
0.13
23
120
228
1872
1.51
3.94
6.6
6.1
11.83
11.14
umol/l
0.29
218
1771
6
5
12.15
3.77
1.0
1.8
—
—
—
0
0
8
12
6.78
3.69
3.5
7.1
—
—
—
0
0
8
12
6.78
3.69
2.0
1.9
39.88
58.78
ug/l
—
8
12
364
3366
1.98
3.56
23.8
14.3
25.70
22.78
mg/l
0.94
313
2664
90
621
1.58
3.41
1.3
1.3
55.79
38.79
iu/ml
0.28
23
210
226
1886
1.46
3.38
2.7
2.7
—
—
—
0
0
37
202
1.92
3.20
1.1
1.4
—
32.82
—
0
15
7
13
5.46
2.88
2.0
2.3
—
—
—
0
0
10
28
3.64
2.80
1.0
1.1
—
—
—
0
0
6
10
6.07
2.70
1.3
1.3
132.70
123.45
iu/ml
—
6
10
9
25
3.66
2.59
1.8
1.6
—
—
—
0
0
9
25
3.66
2.59
1.8
1.6
—
—
—
0
0
122
948
1.41
2.52
4.5
3.0
0.18
0.48
e6/l
2.98
96
700
13
51
2.60
2.47
1.3
1.5
—
—
—
0
0
39
238
1.71
2.40
1.8
1.5
—
—
—
0
0
99
747
1.43
2.39
1.2
1.2
2.80
1.81
u/ml
0.20
22
193
13
52
2.55
2.38
1.3
1.5
—
—
—
0
0
11
39
2.87
2.36
1.6
1.7
—
—
—
0
0
11
39
2.87
2.36
1.6
1.7
—
—
—
0
0
11
39
2.87
2.36
1.6
1.7
—
—
—
0
0
110
850
1.41
2.33
1.6
1.5
19.83
21.85
nmol/l
0.74
91
713
357
3355
1.64
2.30
5.1
4.7
4.72
4.72
mmol/l
0.01
341
3083
363
3429
1.68
2.25
5.5
5.3
2.77
2.76
mmol/l
0.11
343
3137
375
3579
1.86
2.17
28.1
17.3
92.90
76.12
umol/l
3.98
375
3579
12
49
2.49
2.12
2.9
1.2
—
—
—
0
0
354
3333
1.57
2.11
5.1
4.6
1.46
1.53
mmol/l
2.33
336
3048
44
289
1.59
2.06
3.8
2.6
61.37
63.91
ml/min/173m2
0.20
27
126
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
19
99
1.97
1.93
2.7
2.2
0.33
0.36
u/ml
0.13
11
52
12
52
2.35
1.89
1.2
1.5
—
—
—
0
0
15
72
2.13
1.88
1.3
1.4
—
—
—
0
0
8
28
2.89
1.87
7.4
2.4
—
—
—
0
0
5
12
4.21
1.83
1.0
4.9
202.00
240.17
u/l
—
5
12
11
48
2.33
1.72
1.3
1.1
—
—
—
0
0
11
48
2.33
1.72
1.3
1.1
327.33
286.35
u/ml
—
6
23
352
3339
1.48
1.69
5.5
4.8
5.95
5.99
mmol/l
0.20
330
3025
82
635
1.37
1.69
4.7
4.6
21.87
21.11
%
0.16
33
319
340
3208
1.42
1.65
7.5
6.1
40.01
40.21
mmol/mol
0.16
318
2964
10
43
2.36
1.60
1.0
1.1
—
—
—
0
0
10
44
2.30
1.56
1.1
1.2
—
94.00
—
0
5
340
3218
1.39
1.53
4.8
4.2
1.41
1.27
mmol/l
3.49
317
2922
47
340
1.43
1.44
2.8
3.5
—
—
—
0
0
5
17
2.96
1.36
1.4
1.6
—
—
—
0
0
5
17
2.96
1.36
1.4
1.6
—
—
—
0
0
372
3597
1.54
1.29
14.6
10.9
24.97
24.80
u/l
0.08
361
3455
12
62
1.96
1.29
1.8
1.6
—
—
—
0
0
12
62
1.96
1.29
1.8
1.6
—
—
—
0
0
8
35
2.31
1.27
1.4
1.4
—
—
—
0
0
6
25
2.42
1.25
1.3
1.4
—
—
—
0
0
15
85
1.79
1.24
1.2
1.4
—
—
—
0
0
97
804
1.27
1.24
5.7
5.2
1.99
2.87
ug/l
0.88
85
713
16
261
0.60
1.22
1.6
1.8
—
—
—
0
0
10
51
1.99
1.12
1.3
1.5
—
—
—
0
0
10
51
1.99
1.12
1.3
1.5
—
—
—
0
0
18
112
1.64
1.11
1.2
1.9
37.51
37.38
g/l
0.03
11
102
15
89
1.71
1.09
3.5
2.2
2.05
1.63
mg/l
0.97
15
79
10
52
1.95
1.07
1.3
1.5
—
—
—
0
0
125
1085
1.22
1.05
3.2
3.1
32.44
30.87
u/l
0.18
120
1034
5
22
2.29
1.03
1.2
1.1
6.60
28.19
u/l
—
5
22
9
47
1.94
1.02
1.0
1.1
—
—
—
0
0
14
83
1.71
1.02
1.2
1.2
—
—
—
0
0
5
23
2.19
0.98
1.4
1.6
—
—
—
0
0
0
30
0.00
0.97
0.0
2.3
—
—
—
0
0
6
27
2.24
0.94
1.5
1.1
—
—
—
0
0
14
86
1.65
0.92
1.6
1.5
—
—
—
0
0
18
119
1.54
0.89
2.3
2.5
—
—
—
0
0
48
380
1.30
0.89
2.8
2.5
11.17
7.58
umol/l
0.24
43
337
13
80
1.65
0.85
1.1
1.1
—
—
—
0
0
14
88
1.61
0.85
1.8
1.6
17440.56
23753.83
e6/l
—
9
63
35
451
0.75
0.84
9.9
7.3
—
—
—
0
0
8
46
1.75
0.83
1.5
1.5
—
—
—
0
0
14
89
1.59
0.82
1.5
1.5
—
—
—
0
0
11
66
1.69
0.79
1.9
1.5
—
—
—
0
0
5
25
2.01
0.73
1.0
1.0
—
—
—
0
0
47
385
1.25
0.69
1.8
1.8
—
—
—
0
0
15
102
1.49
0.68
1.5
1.4
300.50
299.22
ug/g
—
8
60
26
197
1.34
0.68
2.3
1.4
—
—
—
0
0
5
28
1.80
0.66
1.2
1.1
—
—
—
0
0
376
3690
1.36
0.65
34.5
21.5
39.74
39.86
%
0.16
366
3453
376
3692
1.35
0.63
34.6
21.5
253.67
250.71
e9/l
0.35
371
3594
0
23
0.00
0.58
0.0
1.3
—
—
—
0
0
6
35
1.72
0.58
1.0
1.1
—
—
—
0
0
86
763
1.16
0.57
1.9
1.7
620.78
460.07
pmol/l
0.41
77
624
14
98
1.44
0.57
1.6
1.3
—
—
—
0
0
9
60
1.51
0.54
1.6
1.6
—
—
—
0
0
6
38
1.59
0.54
1.0
1.1
—
—
—
0
0
46
389
1.21
0.53
1.8
1.9
—
—
—
0
0
35
288
1.24
0.52
3.7
5.9
1.04
1.34
mmol/l
2.46
35
282
6
100
0.59
0.52
1.7
1.4
—
—
—
0
0
26
209
1.26
0.48
1.5
1.8
—
—
—
0
0
7
49
1.44
0.46
1.7
1.6
—
—
—
0
0
45
386
1.19
0.46
3.2
6.7
12.90
12.16
kpa
0.46
45
372
45
386
1.19
0.46
3.2
6.7
5.30
5.10
kpa
0.60
45
372
38
322
1.20
0.44
3.5
7.1
124.55
120.00
g/l
0.76
38
316
7
51
1.38
0.44
1.0
1.1
—
—
—
0
0
5
31
1.62
0.43
1.2
1.6
—
25.83
—
0
6
46
399
1.17
0.42
3.8
4.3
6.27
17.36
ug/l
0.53
40
334
68
757
0.88
0.42
5.8
4.3
1.02
1.02
kg/l
0.06
22
103
0
16
0.00
0.41
0.0
1.6
—
—
—
0
0
88
961
0.89
0.40
1.7
1.6
1.52
1.34
mmol/l
1.41
76
797
0
18
0.00
0.40
0.0
1.3
—
—
—
0
0
60
535
1.14
0.39
3.2
2.8
3.14
2.97
e6/l
0.05
32
275
86
937
0.90
0.38
5.3
4.1
0.00
0.00
estimate
-0.00
33
311
9
69
1.31
0.37
1.1
1.4
—
—
—
0
0
9
69
1.31
0.37
1.1
1.4
—
—
—
0
0
44
385
1.16
0.37
3.2
6.8
0.96
1.37
mmol/l
0.35
34
315
5
37
1.36
0.37
1.2
1.5
12.67
17.88
ug/l
—
5
37
59
530
1.13
0.35
1.3
1.4
—
—
—
0
0
10
73
1.38
0.35
1.5
1.5
—
—
—
0
0
130
1378
0.92
0.33
3.9
3.8
41.78
37.42
ng/l
0.10
97
1003
6
46
1.31
0.33
1.5
1.7
—
—
—
0
0
37
323
1.16
0.33
1.5
1.7
1.47
1.50
%
0.11
31
280
18
146
1.24
0.32
7.6
3.1
24.51
24.44
mmol/l
0.04
18
141
12
92
1.31
0.32
1.2
1.7
—
—
—
0
0
15
120
1.26
0.30
1.3
2.3
0.68
1.18
g/l
—
9
108
7
54
1.30
0.30
1.4
1.6
—
—
—
0
0
12
93
1.30
0.30
1.0
1.7
—
—
—
0
0
17
206
0.82
0.29
1.4
1.9
—
—
—
0
0
15
183
0.81
0.28
1.5
1.7
—
—
—
0
0
51
462
1.12
0.28
6.0
4.7
33.56
32.73
%
0.22
39
294
63
579
1.10
0.27
3.1
2.6
0.95
1.12
e6/l
0.21
35
315
176
1692
1.07
0.26
4.5
3.8
0.00
0.00
estimate
0.50
36
343
9
77
1.17
0.24
1.2
1.2
444.33
535.86
mg/l
—
9
72
11
88
1.26
0.22
1.4
1.3
—
—
—
0
0
5
40
1.25
0.22
1.0
1.1
—
—
—
0
0
51
469
1.10
0.22
3.6
3.1
0.73
0.76
ug/l
0.11
36
317
13
107
1.22
0.22
1.3
1.6
—
—
—
0
0
0
11
0.00
0.21
0.0
1.4
—
—
—
0
0
0
11
0.00
0.21
0.0
2.1
—
2.88
—
0
5
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
8
104
0.76
0.21
1.0
1.4
—
—
—
0
0
126
1312
0.94
0.20
4.7
4.0
—
—
—
0
0
10
81
1.24
0.19
1.5
1.6
—
—
—
0
0
7
62
1.13
0.17
1.7
1.6
—
—
—
0
0
8
69
1.16
0.16
1.1
1.2
3.53
3.79
mmol/l
—
8
64
15
130
1.16
0.16
2.4
4.1
1.21
1.36
mmol/l
0.45
15
124
6
77
0.78
0.15
1.0
1.2
—
—
—
0
0
176
1715
1.05
0.15
4.6
3.8
0.00
0.01
estimate
0.50
34
307
53
502
1.06
0.13
1.5
1.4
—
—
—
0
0
5
44
1.14
0.10
1.2
1.5
—
—
—
0
0
5
45
1.11
0.10
1.6
1.9
—
—
—
0
0
20
217
0.92
0.09
3.5
7.1
24.89
24.67
mmol/l
0.10
20
206
173
1700
1.03
0.09
5.6
5.1
0.00
0.00
estimate
-0.00
35
313
16
175
0.91
0.08
1.3
1.3
—
—
—
0
0
7
64
1.10
0.08
1.3
1.2
51.57
23.44
u/l
—
7
55
18
166
1.09
0.08
2.3
2.4
0.56
0.65
%
0.99
18
166
22
207
1.07
0.06
1.7
2.9
13.28
45.75
u/ml
1.93
22
201
12
109
1.10
0.06
2.2
1.3
—
—
—
0
0
111
1090
1.03
0.06
3.5
3.1
4599.61
1255.08
ng/l
1.21
97
921
17
161
1.06
0.03
1.1
1.0
—
—
—
0
0
12
112
1.07
0.03
1.2
1.2
—
—
—
0
0
12
113
1.06
0.02
1.2
1.2
—
—
—
0
0
11
117
0.94
0.01
1.7
2.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.2
—
—
—
0
0
9
98
0.92
-0.00
1.7
1.5
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.9
—
1.20
—
0
9
0
6
0.00
-0.00
0.0
1.5
—
53.67
—
0
6
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
6
61
0.98
-0.00
3.0
3.5
58.83
59.62
%
—
6
61
Mortality – FinRegistry
↥Association
Association between endpoint CD2_BENIGN_PARATHYROID and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| CD2_BENIGN_PARATHYROID | 1.159 [1.0, 1.35] | 0.058 |
| Birth year | 0.995 [0.99, 1.0] | 0.266 |
During the follow-up period (1.1.1998 — 31.12.2019), 274 out of 1306 females with CD2_BENIGN_PARATHYROID died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| CD2_BENIGN_PARATHYROID | 1.321 [1.02, 1.71] | 0.035 |
| Birth year | 0.989 [0.98, 1.0] | 0.021 |
During the follow-up period (1.1.1998 — 31.12.2019), 101 out of 462 males with CD2_BENIGN_PARATHYROID died.
Mortality risk
Mortality risk for people of age
years, who have CD2_BENIGN_PARATHYROID.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.131% | 0.225% |
| 5 | 0.641% | 1.462% |
| 10 | 1.589% | 3.921% |
| 15 | 3.173% | 7.784% |
| 20 | 5.666% | 13.282% |
Relationships between endpoints
↥Index endpoint: CD2_BENIGN_PARATHYROID – Benign neoplasm: Parathyroid gland
GWS hits: 1
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data